Germany’s CureVac, which is gearing up to publish results of a key Covid-19 vaccine trial, said U.S. export restrictions on key materials are making it impossible to predict the company’s short-term supply ramp-up in Europe.
European countries prepared on April 21 to resume deliveries of Johnson & Johnson’s Covid-19 vaccine and speed up the rollout after Europe’s drug regulator backed the shot.
Johnson & Johnson said on April 20 the company will resume rolling out its Covid-19 vaccine in Europe after the region’s medical regulator said the benefits of the shot outweigh the risk of very rare, potentially lethal blood clots.
The U.S. State Department will boost its “Do Not Travel” guidance to about 80 percent of countries worldwide, citing “unprecedented risk to travelers” from the Covid-19 pandemic.
U.S. federal health agencies on April 13 recommended pausing the use of Johnson & Johnson’s Covid-19 vaccine after six women under 50 given the shot developed rare blood clots, dealing a fresh setback to efforts to tackle the pandemic.
Europe’s drug regulator is reviewing reports of rare blood clots in four people who received Johnson & Johnson’s Covid-19 vaccine and expanded its probe into AstraZeneca’s shot to include reports of a bleeding condition.
McCann Health on April 7 announced two key appointments to its leadership team in Europe: Saturnino Izquierdo has taken on an expanded role of President, Europe and LATAM and Jonathan Kukathasan was promoted to President, UK, McCann Health.
The World Health Organization expects there will be no reason to change its assessment that the benefits of the AstraZeneca vaccine against Covid-19 outweigh any risks, a regulatory official told a news conference on April 6.
Coronavirus-related deaths worldwide crossed 3 million on April 6, according to a Reuters tally, as the latest global resurgence of Covid-19 infections is challenging vaccination efforts across the globe.
EU leaders voiced frustration on March 25 over a massive shortfall in contracted deliveries of AstraZeneca Covid-19 vaccines, as a third wave of infections surged across Europe.